Brant Point Investment Management LLC purchased a new stake in Flexion Therapeutics Inc (NASDAQ:FLXN) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 104,855 shares of the specialty pharmaceutical company’s stock, valued at approximately $2,626,000.
Several other hedge funds and other institutional investors have also made changes to their positions in FLXN. Advisory Services Network LLC purchased a new stake in shares of Flexion Therapeutics in the fourth quarter valued at about $108,000. SG Americas Securities LLC purchased a new stake in shares of Flexion Therapeutics in the third quarter valued at about $135,000. IFP Advisors Inc lifted its holdings in shares of Flexion Therapeutics by 58.1% in the third quarter. IFP Advisors Inc now owns 8,030 shares of the specialty pharmaceutical company’s stock valued at $194,000 after purchasing an additional 2,950 shares in the last quarter. State Board of Administration of Florida Retirement System purchased a new stake in shares of Flexion Therapeutics in the third quarter valued at about $235,000. Finally, Teacher Retirement System of Texas purchased a new stake in shares of Flexion Therapeutics in the fourth quarter valued at about $245,000. 80.47% of the stock is currently owned by institutional investors.
Flexion Therapeutics Inc (NASDAQ FLXN) opened at $25.36 on Thursday. The company has a debt-to-equity ratio of 0.87, a current ratio of 12.93 and a quick ratio of 12.93. The firm has a market cap of $952.04, a P/E ratio of -7.20 and a beta of 0.91. Flexion Therapeutics Inc has a 52-week low of $16.51 and a 52-week high of $32.25.
Flexion Therapeutics Company Profile
Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.
Want to see what other hedge funds are holding FLXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Flexion Therapeutics Inc (NASDAQ:FLXN).
Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.